Category |
Medicine, Research & Experimental |
Manuscript Type |
Autobiography |
Article Title |
Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines
|
Manuscript Source |
Invited Manuscript |
All Author List |
Daniele Baiz, Barbara Dapas, Rossella Farra, Bruna Scaggiante, Gabriele Pozzato, Fabrizio Zanconati, Nicola Fiotti, Lara Consoloni, Sara Chiaretti and Gabriele Grassi |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
“Fondazione Cassa di Risparmio of Trieste" |
|
“Fondazione Benefica Kathleen Foreman Casali of Trieste” |
|
Italian Minister of Instruction, University and Research (MIUR), PRIN 2010-11 (in part) |
20109PLMH2 |
|
Corresponding Author |
Gabriele Grassi, MD, PhD, Department of Life Sciences, University Hospital of Cattinara, Strada di Fiume 447, 34100 Trieste, Italy. ggrassi@units.it |
Key Words |
Bortezomib; Cyclins; E2F family; Hepatocellular carcinoma; Liver; Microarray; 26S proteasome |
Core Tip |
The 26S proteasome inhibitor bortezomib has been proposed as a novel therapeutic molecule for hepatocellular carcinoma (HCC), being able to reduce cell growth. Little information is available on the effect of bortezomib (BZB) on many of E2Fs, a family of transcription factors regulating normal and tumor cell proliferation. Our data show, for the first time, the BZB effect on expression of E2F family members in HCC cell lines is not limited to the most studied E2F1, but, it extends also to other E2F members, in particular E2F2, E2F8 and E2F6, and the effect is phenotypic dependent. |
Publish Date |
2014-02-19 16:57 |
Citation |
Baiz D, Dapas B, Farra R, Scaggiante B, Pozzato G, Zanconati F, Fiotti N, Consoloni L, Chiaretti S, Grassi G. Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines. World J Gastroenterol 2014; 20(3): 795-803 |
URL |
http://www.wjgnet.com/1007-9327/full/v20/i3/795.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v20.i3.795 |